Medications affecting the IGF-1/Growth Hormone Axis, including teprotumumab, somatostatin analogues and anti-CGRP monoclonal antibodies, are associated with an elevated reporting odds of alopecia in women; a pharmacovigilance study - SUPPLEMENTAL MATERIAL

Abstract

Supplemental data for publication: Medications affecting the IGF-1/Growth Hormone Axis, including teprotumumab, somatostatin analogues and anti-CGRP monoclonal antibodies, are associated with an elevated reporting odds of alopecia in women; a pharmacovigilance studyTHIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE. TO VIEW A LIST OF FILES AND ACCESS THE FILES IN THIS DATASET CLICK ON THE DOI-LINK ABOV